Systemic lupus erythematosus (SLE) is a common rheumatic disease involving multiple organs and is also a typical autoimmune disease. However, with the rapid development of medicine, immunology, pharmacology and molecular biology in recent times, the pathogenesis of the disease has been further understood and SLE can be diagnosed and treated at an early stage, and with the improvement of treatment and the emergence of new drugs, the prognosis of patients has been greatly improved. The prognosis of patients has been greatly improved, and the disease has been transformed from “incurable” to curable, and patients can study, work and live as normal people. Although the understanding of the pathogenesis of SLE continues to improve, and many important discoveries and research results have been made, the exact cause of the disease is still not clear. Nowadays, the clear mechanism is the disturbance of the immune system, which is manifested by the hyperfunction of T and B lymphocytes, the production of a large number of autoantibodies, and the formation of immune complexes, which leads to the development of the disease. Most of the current treatments and drugs for SLE are based on correcting the dysfunction of the immune system, such as the use of glucocorticoids, chloroquine, hydroxychloroquine, methotrexate (MTX), cyclophosphamide (CTX), azathioprine (AZA) and other drugs to suppress and regulate the dysfunctional immune system, and newer developments will include biological agents targeting the MHC-antigen- TCR trimeric complex, cytokines and other immune pathways, as well as stem cell transplantation. and stem cell transplantation. Glucocorticoids are the most powerful immunosuppressive drugs and the most commonly used drugs. Since glucocorticoids have many side effects, such as infection, osteoporosis, diabetes, osteonecrosis, and hypertension, it is important to use them appropriately. It is also very dangerous for patients to stop using hormones without authorization, which may even cause acute attacks of the disease. The treatment regimen and dosage must be tailored to the specific circumstances of the disease. The combination of small doses of hormones and drugs such as MTX or chloroquine can reduce the dosage of hormones, which not only has good efficacy in treating patients with mild to moderate SLE, but also has little side effects and seeks a higher quality of life for patients. However, for the treatment of lupus nephritis, CNS lupus and lupus thrombocytopenic purpura, larger doses of hormones and immunosuppressants should be applied according to specific conditions to achieve faster remission. On the other hand, comprehensive treatment such as blood pressure control, blood sugar and calcium supplementation should be strengthened.